Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Significant number of young women fail to recognize recent weight gain

Despite popular belief about women's weight concerns, young women commonly fail to recognize recent gain of as many as 11 pounds - putting them at risk for cardiovascular disease and other obesity-related conditions.

11 Jan 2012

Shire, Janssen enter development and marketing agreement for Resolor

Shire plc, the global specialty biopharmaceutical company, announced today that it has acquired the rights to develop and market Resolor (prucalopride) in the United States (US) in an agreement with Janssen Pharmaceutica N.V.

11 Jan 2012

Grief and heart attacks linked: Study

Researchers have found that grief might actually break ones heart. A new study shows that people grieving the death of a close loved one could have a heart attack risk that is 20 times higher than normal.

10 Jan 2012

Shire acquires rights to develop and market Resolor in the U.S.

10 Jan 2012

Researchers use 3-D imaging to identify proteins involved in arterial stiffness

Human arteries - some smaller than a strand of hair - stiffen as a person ages. This stiffening is a factor in cardiovascular disease, the leading cause of death in the United States, because it contributes to the circulatory complications in disorders such as high blood pressure and diabetes. University of Missouri researchers have now used advanced 3-D microscopic imaging technology to identify and monitor the proteins involved in this stiffening process.

10 Jan 2012

Study demonstrates that individuals can eat out and still lose weight

Going out to eat has become a major part of our culture. Frequently eating out and consuming high-calorie foods in large portions at restaurants can contribute to excess calorie intake and weight gain. However, a study in the January/February 2012 issue of the Journal of Nutrition Education and Behavior demonstrates that individuals can eat out and still lose weight.

10 Jan 2012

Study identifies netrin-1 as novel target for atherosclerosis

A new study by NYU Langone Medical Center researchers identified a new culprit that leads to atherosclerosis, the accumulation of fat and cholesterol that hardens into plaque and narrows arteries. The research, published online by Nature Immunology on January 8, 2012, explains why cholesterol-laden, coronary artery disease-causing cells called macrophages, accumulate in artery plaques.

10 Jan 2012

JHM, Healthways partner for innovative weight-loss program

Building on the success of recent Hopkins research showing obese participants were able to lose significant weight and keep it off for two years using telephone coaching and a specially designed website, Johns Hopkins Medicine is collaborating with Healthways to help bring the innovative weight-loss program to many more who could benefit from it.

9 Jan 2012

Novel target in artery plaque identified as potential therapeutic intervention

A new study by NYU Langone Medical Center researchers identified a new culprit that leads to atherosclerosis, the accumulation of fat and cholesterol that hardens into plaque and narrows arteries.

9 Jan 2012

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Human Genome Sciences, Inc. will today announce its priority goals for 2012 and report on progress with the commercialization of BENLYSTA (belimumab), the first approved drug for systemic lupus in 56 years, during a presentation this afternoon by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 30th Annual JPMorgan Healthcare Conference in San Francisco.

9 Jan 2012

Middle-aged adults with diabetes have time to learn how to control hypertension

A new study suggests that middle-aged adults recently diagnosed with diabetes and hypertension have time to try to learn how to control their high blood pressure without medications, but not too much time.

9 Jan 2012

miRagen, Silence partner to assess delivery potential of novel miRNA-based therapeutics

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces that it has signed an agreement with miRagen Therapeutics, Inc., to assess the delivery potential of Silence's proprietary DBTC delivery system with miRagen's novel microRNA-based therapeutics.

9 Jan 2012

Statin use may influence susceptibility to ILD in smokers

Use of statins may influence susceptibility to or the progression of interstitial lung disease (ILD) in smokers, according to a new study.

6 Jan 2012

CRF sponsors Seventh International Conference on Cell Therapy for Cardiovascular Disease

The Seventh International Conference on Cell Therapy for Cardiovascular Disease sponsored by the Cardiovascular Research Foundation (CRF) is a comprehensive program dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease, as well as related diseases such as diabetes and stroke.

5 Jan 2012

Repeated episodes of depression contribute to inflammation

An important ongoing debate in the field of psychiatry is whether inflammation in the body is a consequence of or contributor to major depression. A new study in Biological Psychiatry has attempted to resolve the issue.

5 Jan 2012

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive preliminary results from its ongoing clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

5 Jan 2012